business
Maryland Board Establishes $204 Monthly Cap on Jardiance for Public Purchases by 2027
The Maryland Prescription Drug Affordability Board has established an upper payment limit for Jardiance, a type 2 diabetes medicine, capping its price at $204 for a 30-day supply by January 2027. The board will oversee a process to lower costs for state and local governments. The move is estimated to save $320,000 annually.
Apr 13, 9:59 PM·1m read2 sources
ST
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
The Maryland Prescription Drug Affordability Board set an upper payment limit for Jardiance, a type 2 diabetes medicine.
The board will oversee a process to lower the cost of Jardiance for the state and local governments by January 2027. The price of Jardiance will be capped at $204 for a 30-day supply by January 2027. 80 a pill for a 30-day supply by January 2027.
The move to cap the price of Jardiance is estimated to save $320,000 a year. Andrew York, the executive director of the Maryland Prescription Drug Affordability Board, stated that the expected cost for Jardiance was benchmarked against the maximum fair price paid by Medicare. The 2027 pricing for Jardiance was adjusted for inflation, according to Andrew York.
The Maryland Prescription Drug Affordability Board is designed to function like a state utility commission.
The upper payment limit for Jardiance marks the second time a state panel has taken such a step.
The board's action addresses the cost of Jardiance for public entities in Maryland.
Savings from the cap will apply to expenditures by state and local governments starting in 2027.
